Cognition Therapeutics, Inc. (CGTX)
| Market Cap | 65.33M -56.2% |
| Revenue (ttm) | n/a |
| Net Income | -15.99M |
| EPS | -0.18 |
| Shares Out | 95.09M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 282,749 |
| Open | 0.6450 |
| Previous Close | 0.6354 |
| Day's Range | 0.6320 - 0.6975 |
| 52-Week Range | 0.5501 - 1.8250 |
| Beta | 1.80 |
| Analysts | Strong Buy |
| Price Target | 3.33 (+385.15%) |
| Earnings Date | Nov 5, 2026 |
About CGTX
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is zervimesine, an orally delivered small molecule to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, which is in Phase 2 clinical studies for the treatment of Alzheimer’s disease and Mild Cognitive Impairment, as well as geographic atr... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for CGTX stock is "Strong Buy." The 12-month stock price target is $3.33, which is an increase of 385.15% from the latest price.
News
Cognition Therapeutics Earnings Call Transcript: Q3 2026
FDA alignment sets a path for a single pivotal DLB study, targeted to start in mid-2027. Cash runway extends into Q4 2027, while START results are expected in H2 2027.
Cognition Therapeutics Earnings release: Q3 2026
Cognition Therapeutics released its Q3 2026 earnings on November 5, 2026, summarizing the period's financial results.
Cognition Therapeutics Quarterly report: Q3 2026
Cognition Therapeutics has published its Q3 2026 quarterly earnings report on November 5, 2026.
Cognition Therapeutics reports Q3 EPS (4c), consensus (7c)
Estimates that it has sufficient cash to fund operations and capital expenditures into the fourth quarter of 2027. Lisa Ricciardi, Cognition’s president and CEO stated, “The work we conducted with…
Cognition Therapeutics Reports Financial Results for the Third Quarter 2026 and Provides Business Update
PURCHASE, N.Y., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders (the “Compa...
Cognition Therapeutics to Host Third Quarter 2026 Financial Results and Business Update Call on November 5, 2026
-- Conference Call and Webcast 8:30 a.m. ET November 5 -- PURCHASE, N.Y., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company developing product can...
Cognition Therapeutics aligns with FDA on Phase 3 trial of zervimesine
Cognition Therapeutics (CGTX) has aligned with the U.S. FDA on key elements of a Phase 3 study in dementia with Lewy bodies including patient selection, dose, duration, and endpoints. The…
Cognition Therapeutics Announces Alignment with FDA on Pivotal Phase 3 Trial of Zervimesine (CT1812) in Dementia with Lewy Bodies
PURCHASE, N.Y., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical-stage company developing product candidates that treat neurodegene...
Cognition Therapeutics issued patent covering novel crystalline form UPSTO
Cognition Therapeutics (CGTX) announced that the United States Patent and Trademark Office, or USPTO, has granted the company a patent covering a novel crystalline form, or polymorph, of zervimesine, ...
Cognition Therapeutics issued patent extending protection for zervimesine
Cognition Therapeutics (CGTX) announced that the United States Patent and Trademark Office has granted the company a patent covering a novel crystalline form, or polymorph, of zervimesine (CT1812), th...
Cognition Therapeutics Announces Issuance of Composition of Matter Patent, Extending Protection for Zervimesine (CT1812) Through 2045
- An additional five years of patent protection may be possible through a standard extension - - An additional five years of patent protection may be possible through a standard extension -
Cognition Therapeutics schedules Type C meeting with FDA for trial of CT1812
Cognition Therapeutics (CGTX) announced that a Type C meeting with the U.S. Food and Drug Administration, FDA, Division of Neurology has been scheduled for October 20, 2026. The objective of…
Cognition Therapeutics Schedules a Type C Meeting with FDA to Align on Endpoints for Phase 3 Trial of Zervimesine (CT1812) in DLB
October 20th Meeting with the Division of Neurology Expected to Define Endpoint for Phase 3 October 20th Meeting with the Division of Neurology Expected to Define Endpoint for Phase 3
Cognition Therapeutics to Present at H.C. Wainwright Global Investment Conference
PURCHASE, N.Y., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that the Com...
Cognition Therapeutics reports Q2 EPS (4c), consensus (6c)
As of June 30, 2026, the company reported having approximately $34.8M in cash, cash equivalents, and restricted cash equivalents, alongside $21.6M in total obligated grant funds remaining from the Nat...
Cognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business Update
PURCHASE, N.Y., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders (the “Compa...
Cognition Therapeutics Earnings release: Q2 2026
Cognition Therapeutics released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Cognition Therapeutics Quarterly report: Q2 2026
Cognition Therapeutics has published its Q2 2026 quarterly earnings report on August 6, 2026.
Cognition Therapeutics Slides: Investor presentation
Cognition Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on August 1, 2026.
Cognition Therapeutics Participating in Fireside Chat at B. Riley Securities' Mind, Muscle & Vision Summit
PURCHASE, N.Y., July 13, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that the Comp...
Cognition Therapeutics gets FDA feedback on zervimesine study
Cognition Therapeutics (CGTX) announced that it received written feedback from the FDA following its recent meeting. The FDA agreed that psychosis associated with dementia with Lewy bodies could be an...
Cognition Therapeutics Aligns on Key Aspects of Pivotal Study for Zervimesine (CT1812) in DLB Psychosis Following Receipt of FDA Meeting Minutes
- Zervimesine Would be the First Long-term, Durable Treatment Option with an Impact on Underlying Disease - - Company Developing NPI as a Measure of DLB Psychosis -
Cognition Therapeutics Transcript: AGM 2026
The meeting was held virtually, confirming quorum and addressing two proposals: election of directors and ratification of the auditor. Both proposals passed by the required vote, with final results to be filed in an 8-K. A Q&A session followed the formal meeting.
Cognition Therapeutics gets notice of allowance from USPTO for zervimesine
Cognition Therapeutics (CGTX) announced that a notice of allowance has been received from the United States Patent and Trademark Office, or USPTO, for patent application 19/563,468. The allowed patent...
Cognition Therapeutics Announces New Composition of Matter Patent, Extending Patent Protection for Lead Candidate, Zervimesine (CT1812) Through 2045
PURCHASE, N.Y., June 16, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative di...